INTRA-PERITONEAL DISTRIBUTION OF CHROMIC-P-32 PHOSPHATE SUSPENSION IN THE DOG

Intraperitoneal administration of radioactive chromic phosphate suspension is receiving renewed attention as a therapeutic treatment to limit metastatic dissemination of ovarian carcinoma. Our study utilized mongrel dogs to approximate the uptake and distribution of 3.0 millicuries 32P-chromic phosphate suspension administered intraperitoneally (IP). Lymph nodes, omentum, retroperitoneum, peritoneum, diaphragm, abdominal wall muscle, pleura, spleen, liver, kidneys, lung, small intestine and blood were sampled for liquid scintillation counting and autoradiography. Whole blood showed the least activity (1800 cpm/100 λ at day one, declining to 280 cpm/100 λ by day 16). Omentum and diaphragm maintained the greatest concentrations (183 x 106 dpm/g and 4 x 106 dpm/g respectively.) These initial high values were 100 times greater than the highest values found for the small intestine, abdominal wall muscle, mediastinal and retroperitoneal lymph nodes and pleura. The peritoneum increased in specific activity until day three (5.9 x 106 dpm/g) and then rapidly declined. Our results show that following IP administration to the dog, 32P suspension is associated with the serous membranes of the peritoneal cavity (most notably omentum, diaphragm, peritoneum and retroperitoneum). This distribution could be valuable in adjuvant tumor therapy since serosal surfaces of the peritoneum (both visceral and parietal) and the omentum are the most common sites of tumor metastases associated with ovarian carcinoma. © 1979.